Utility of a population pharmacokinetic meta analysis during the approval process of teduglutide for the treatment of short bowel syndrome.

Abstract

OBJECTIVE:

Teduglutide is a recombinant analogue of human glucagonlike peptide-2 (GLP-2) that was recently approved by the US and European regulatory agencies FDA and EMA for the treatment of short bowel syndrome (SBS). The objectives of this work were, firstly, to develop a population pharmacokinetic (popPK) model based on the available PK data of the entire clinical development program and, secondly, to utilize the model for the justification of the proposed dosing regimen. The exploratory analysis was based on a previously established structural PK model and focused primarily on the investigation of covariate effects.

RESULTS:

The plasma concentrationtime profiles of teduglutide after subcutaneous application were adequately described by a 1-compartment model with first order absorption and elimination. The area under the curve (AUC) was lower for male subjects, for subjects with higher creatinine clearance, for overweight subjects, and for SBS patients. However, except for subjects with severe renal impairment no clinically relevant effects on AUC were identified.

CONCLUSION:

Our model-based analysis supports the approved dose adjustment for SBS patients with and without renal impairments maintaining the exposure in a value range with acceptable variance for the target population.

• Authors: Stefan Roepcke, Ruediger Nave, Jane Cyran, Nele Plock, Gezim Lahu, Axel Facius
• Journal: International journal of clinical pharmacology and therapeutics (Int J Clin Pharmacol Ther) Vol. 52 Issue 12 Pg. 1045-58 (Dec 2014) ISSN: 0946-1965 [Print] Germany
• PMID: 25066226 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Peptides
• teduglutide

Topics

• Adolescent
• Adult
• Aged
• Drug Approval
• Drug Interactions
• Female
• Humans
• Male
• Meta-Analysis as Topic
• Middle Aged
• Models, Biological
• Peptides (pharmacokinetics, therapeutic use)
• Renal Insufficiency (metabolism)
• Short Bowel Syndrome (drug therapy)